Status:
ACTIVE_NOT_RECRUITING
Post Market Clinical Follow-Up KeriFuse®
Lead Sponsor:
Keri Medical SA
Conditions:
Arthritis
Eligibility:
All Genders
18+ years
Brief Summary
The general objective of this study is to evaluate the performances and the safety related to the KeriFuse® intramedullary arthrodesis implant and associated instrumentation used in accordance with th...
Eligibility Criteria
Inclusion
- Patients ≥ 18 years,
- Patients that will have a surgery using a KeriFuse® implant in accordance with the approved labelling and IFU.
Exclusion
- Pregnant or nursing women,
- Patients with intellectual disabilities who cannot follow the instructions of their surgeon,
- Patients with a contraindication to surgery and more specifically to the implantation of KeriFuse®,
- Patients with acute or chronic infections, local or systemic,
- Patients with sensitivities or allergies to the implant components (Nickel, Titanium).
Key Trial Info
Start Date :
July 5 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2027
Estimated Enrollment :
97 Patients enrolled
Trial Details
Trial ID
NCT06546332
Start Date
July 5 2022
End Date
March 1 2027
Last Update
September 11 2025
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre de la main du Pays d'Aix
Aix-en-Provence, France, 13090
2
Clinique de la Chataigneraie
Beaumont, France, 63110
3
Centre Ostéo Articulaire Fleming
Bourgoin, France, 38300
4
Clinique Saint François
Nice, France, 06000